News

HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment

PDS-2™ mentioned in Medical Device And Diagnostic Industry, Apr 19, 2021

PDS-2™ featured in FDA’s “Reflections on a Record Year for Novel Device Innovation Despite COVID-19 Challenges” report, Feb 16, 2021

PDS-2™ System Pivotal Trial Results Published in the Journal of American College of Cardiology, Dec 22, 2020.Download

Dr. Brian Ghoshhajra Details the Significance of the PDS-2™ System in Affecting Progression of HoFH, Dec 5, 2019

HDL Therapeutics Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia Selected as a 2019 Best of American Heart Association Specialty Conference Presentation, Nov 17 2019Download
HDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia: May 15 2019Download
Coronary Atheroma Regression from Serial Infusions of Autologous Selectively Delipidated Preβ-HDL-enriched Plasma on Coronary Atheroma in Patients With Homozygous Familial Hypercholesterolemia in the HALO-FH TrialDownload

American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions May 15 2019

A First in Man, Randomized, Placebo Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High Density Lipoprotein Plasma Infusions in Patients With Acute Coronary SyndromeDownload

Journal of The American College of Cardiology. 15:55:2727-2735. 2010.  Waksman, Brewer, et al.

Selective Delipidation of Plasma HDL Enhances Reverse Cholesterol Transport In VivoDownload

Journal of Lipid Research. 50:894-907.2009.  Sacks, Brewer, et al.